De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

4DMedical Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Andreas Fouras

Algemeen directeur

AU$1.1m

Totale compensatie

Percentage CEO-salaris	53.3%
Dienstverband CEO	11.8yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	6.2yrs

Recente managementupdates

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

Oct 26

Recent updates

Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation

Sep 21

We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate

May 08

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

Oct 26

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 16

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 05

Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?

Feb 20

Analyse CEO-vergoeding

Hoe is Andreas Fouras's beloning veranderd ten opzichte van 4DMedical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$1m	AU$602k	-AU$36m
Mar 31 2024	n/a	n/a	-AU$33m
Dec 31 2023	n/a	n/a	-AU$31m
Sep 30 2023	n/a	n/a	-AU$31m
Jun 30 2023	AU$988k	AU$557k	-AU$31m
Mar 31 2023	n/a	n/a	-AU$30m
Dec 31 2022	n/a	n/a	-AU$28m
Sep 30 2022	n/a	n/a	-AU$26m
Jun 30 2022	AU$821k	AU$519k	-AU$25m
Mar 31 2022	n/a	n/a	-AU$23m
Dec 31 2021	n/a	n/a	-AU$21m
Sep 30 2021	n/a	n/a	-AU$21m
Jun 30 2021	AU$646k	AU$502k	-AU$21m
Mar 31 2021	n/a	n/a	-AU$26m
Dec 31 2020	n/a	n/a	-AU$30m
Sep 30 2020	n/a	n/a	-AU$26m
Jun 30 2020	AU$1m	AU$435k	-AU$22m
Mar 31 2020	n/a	n/a	-AU$16m
Dec 31 2019	n/a	n/a	-AU$9m
Sep 30 2019	n/a	n/a	-AU$8m
Jun 30 2019	AU$366k	AU$360k	-AU$6m

Compensatie versus markt: De totale vergoeding ($USD 758.25K ) Andreas } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 306.07K ).

Compensatie versus inkomsten: De vergoeding van Andreas is gestegen terwijl het bedrijf verliesgevend is.

CEO

Andreas Fouras

11.8yrs

Tenure

AU$1,130,101

Compensatie

Dr. Andreas Fouras, BEng, MEngSc(Res), Ph.D. M.A.I.C.D. is Founder of 4DMedical Limited and serves as its Managing Director & Chief Executive Officer and served as its Chief Technology Officer. Dr. Fouras...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Andreas Fouras	Founder	no data	AU$1.13m	0.21% A$ 466.3k
Simon Glover	Chief Financial Officer	2.3yrs	AU$500.15k	0.016% A$ 35.8k
John Livingston	Strategic Advisor & Executive Director	2.4yrs	AU$223.55k	0.47% A$ 1.0m
Matt Tucker	Chief Commercial Officer	1.8yrs	AU$620.89k	geen gegevens
Naomi Lawrie	Company Secretary & General Counsel	1.5yrs	geen gegevens	geen gegevens
Aidan Jamison	Senior Vice President of Engineering	no data	geen gegevens	geen gegevens
Rachael Tenkaten	Senior Vice President of Product	less than a year	geen gegevens	geen gegevens
Greg Mogel	Chief Medical Officer	no data	geen gegevens	geen gegevens
David Hannes	Senior Vice President of Global Business Development	less than a year	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

Ervaren management: Het managementteam van 4DX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Andreas Fouras	Founder	11.8yrs	AU$1.13m	0.21% A$ 466.3k
John Livingston	Strategic Advisor & Executive Director	6.6yrs	AU$223.55k	0.47% A$ 1.0m
Sam Hupert	Member of Advisory Board	5.8yrs	geen gegevens	geen gegevens
Robert Figlin	Independent Non-Executive Director	7.8yrs	AU$82.44k	0.13% A$ 280.8k
Julian Sutton	Non-Executive Director	7.1yrs	AU$247.13k	0.12% A$ 259.6k
Raymond Casciari	Clinical Chair of the Advisory Board	5.4yrs	geen gegevens	geen gegevens
Lilian Bianchi	Independent Non-Executive Chair	4.8yrs	AU$101.85k	0.023% A$ 50.4k
Bruce Thompson	Member of Advisory Board	no data	geen gegevens	geen gegevens
Geraldine McGinty	Independent Non-Executive Director	1.1yrs	AU$55.66k	0.0097% A$ 21.6k

6.2yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 4DX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

4DMedical Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

4DMedical Limited, Annual General Meeting, Nov 20, 2024

4DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

4DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors

4DMedical Limited, Annual General Meeting, Nov 02, 2023

4DMedical Limited Appoints Matt Tucker as Senior Vice President of Business Development and Strategy

Recent updates

Full year 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

4DMedical Limited, Annual General Meeting, Nov 20, 2024

Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation

Consensus revenue estimates fall by 36%

Full year 2024 earnings: EPS and revenues miss analyst expectations

We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate

Consensus revenue estimates fall by 20%

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates decrease by 22%, EPS upgraded

4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million.

4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million.

No longer forecast to breakeven

Price target increased by 21% to AU$1.18

4DMedical Receives U.S. FDA Clearance for CT LVAS Lung Function Scanning Software

Forecast to breakeven in 2026

New major risk - Share price stability

4DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

New minor risk - Market cap size

4DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors

New minor risk - Profitability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

4DMedical Limited, Annual General Meeting, Nov 02, 2023

Forecast to breakeven in 2026

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

First half 2023 earnings released: AU$0.06 loss per share (vs AU$0.04 loss in 1H 2022)

Consensus revenue estimates increase by 55%

We Think 4DMedical (ASX:4DX) Needs To Drive Business Growth Carefully

4DMedical Limited Appoints Matt Tucker as Senior Vice President of Business Development and Strategy

4Dmedical Unveils XV Scanner

Price target increased to AU$1.33

4DMedical Limited Releases CT LVAS in Australia

American Medical Association Current Procedural Terminology Editorial Panel Accepts 4Dmedical's Application for the Addition of A New Category III CPT Code

Is 4DMedical (ASX:4DX) In A Good Position To Deliver On Growth Plans?

4DMedical Limited, Annual General Meeting, Nov 03, 2022

4DMedical Limited Updates Vanderblit 'Burn Pit' Trial Hits Primary Endpoint

Consensus forecasts updated

Full year 2022 earnings: Revenues miss analyst expectations

We're Hopeful That 4DMedical (ASX:4DX) Will Use Its Cash Wisely

4Dmedical Limited Announces CFO Changes

High number of new directors

4DMedical Limited Appoints John Livingston as Role of Senior Strategist and Executive Director

4DMedical Limited Announces Clinical Trial Results Presented At Top US Lung Conference

High number of new directors

Price target decreased to AU$1.50

Price target decreased to AU$1.50

4DMedical Limited Announces Executive Changes

We Think 4DMedical (ASX:4DX) Can Afford To Drive Business Growth

High number of new directors

4DMedical Limited Announces First Commercial Scans with I-MED to Commence in December

Full year 2021 earnings released: AU$0.082 loss per share (vs AU$0.15 loss in FY 2020)

Full year 2021 earnings released

4D Medical Announces Undertaking Clinical Trial At the John Hopkins School of Medicine in Baltimore, USA

4DMedical Limited Commences XV LVAS Clinical Trial at Johns Hopkins School of Medicine, US

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

4DMedical Limited Commences Patient Recruitment for VQ Trial

New 90-day low: AU$1.65

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.04 loss in 1H 2020)

Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?

4DMedical Limited Appoints Mr. Craige Pendleton-Browne as Chief Information Officer

New 90-day low: AU$2.07

4DMedical Limited Provides Update on Its First Clinical Pilot for XV Lung Ventilation Analysis Software

4DMedical Limited Completes First Commercial Scan in Australia

4Dmedical Limited Partners with University of Miami Health System to Establish the Functional Lung Imaging Research Program

4Dmedical Limited Receives TGA Approval for XV Lung Ventilation Analysis Software (XV LVAS)